Zhang Shaobo, Wang Jiabei, Zhu Zebin, Ji Peng, Wang Yanli, Cheng Kun, Nashan Björn, Liu Lianxin, Zhang Shugeng
Department of Liver Transplantation, The First Affiliated Hospital of University of Science and Technology of China, Hefei, People's Republic of China.
Graduate School of Bengbu Medical University, Bengbu, People's Republic of China.
J Hepatocell Carcinoma. 2025 Aug 31;12:2007-2015. doi: 10.2147/JHC.S534271. eCollection 2025.
To evaluate the efficacy and safety of different doses of bevacizumab combined with atezolizumab in patients with unresectable hepatocellular carcinoma.
A retrospective analysis was conducted on clinical data from patients receiving Atezo-Bev therapy at our institution. Patients were stratified into standard-dose (SD) and low-dose (LD) groups based on bevacizumab dosage. Comparative analyses evaluated antitumor efficacy and adverse events (AEs) incidence.
A total of 63 patients were included (SD group: n=32; LD group: n=31). Baseline characteristics showed no significant differences between the groups. Median overall survival (OS) was 22.0 months in the SD group and 19.3 months in the LD group, while median progression-free survival (PFS) was 8.0 months and 6.9 months, respectively. No statistically significant differences were observed in OS or PFS between the two groups (P=0.276 and P=0.297, respectively). However, the incidence of bevacizumab-related AEs was lower in the LD group compared to the SD group.
Compared to low-dose bevacizumab combined with atezolizumab, the standard-dose regimen did not demonstrate significant superiority in OS or PFS. Additionally, the low-dose combination may lead to fewer AEs.
评估不同剂量贝伐单抗联合阿替利珠单抗治疗不可切除肝细胞癌患者的疗效和安全性。
对我院接受阿替利珠单抗联合贝伐单抗治疗患者的临床资料进行回顾性分析。根据贝伐单抗剂量将患者分为标准剂量（SD）组和低剂量（LD）组。比较分析评估抗肿瘤疗效和不良事件（AE）发生率。
共纳入63例患者（SD组：n = 32；LD组：n = 31）。两组基线特征无显著差异。SD组中位总生存期（OS）为22.0个月，LD组为19.3个月，而中位无进展生存期（PFS）分别为8.0个月和6.9个月。两组间OS或PFS均未观察到统计学显著差异（分别为P = 0.276和P = 0.297）。然而，LD组贝伐单抗相关AE的发生率低于SD组。
与低剂量贝伐单抗联合阿替利珠单抗相比，标准剂量方案在OS或PFS方面未显示出显著优势。此外，低剂量联合方案可能导致更少的AE。
